Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of EVT201 capsules versus placebo in patients with insomnia disorder

Next Previous
Trial Profile

A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of EVT201 capsules versus placebo in patients with insomnia disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimdazenil (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Zhejiang Jingxin Pharmaceutical

Most Recent Events

  • 08 Feb 2024 Results assessing efficacy and safety of Dimdazenil in adults with insomnia disorder, published in the Sleep.
  • 05 Dec 2023 Primary endpoint has been met (The average total sleep time (TST) measured by PSG on the 13th/14th night of the double-blind treatment period), according to Results published in the Oxford University Press on behalf of Sleep Research Society
  • 05 Dec 2023 According to Results published in the Oxford University Press on behalf of Sleep Research Society, Wang Yuping, Medical PhD, of Capital Medical University Xuanwu Hospital is the principal investigator of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top